The efficacy and mechanism of Yishen Paidu Formula for chronic kidney disease (stage 4 to 5): a pilot study.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006574

Enrollment

Unknown

Registered

2022-09-09

Start date

2022-09-10

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

group (Yishen Paidu Recipe):Basal treatment+Yishen Paidu Recipe

group(Niaoduqing):Basal treatment+Niaoduqing granule

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? Aged =18 years; ? Chronic kidney disease stage 4 to 5 (non-dialysis) patients. ? Patients agreed to participate in the study with inform consent.

Exclusion criteria

Exclusion criteria: ? Pregnant women or patients in lactating; ? Patients with hyperkalemia, acute heart failure and other conditions which require initiation of dialysis; ? Patients who are taking glucocorticoids or immunosuppressants; ? Patients with inflammatory bowel disease, or patients with severe primary diseases such as active malignant tumor and gastrointestinal bleeding, or patients who cannot cooperate with treatment such as mental illness. ? Patients with acute infection or using antibiotics ? Patients who are taking probiotics, probiotics and other drugs that affect intestinal flora ? Patients who are allergy to the drugs used in the study.

Design outcomes

Primary

Measure	Time frame
estimated glomerular rate filtering;	—

Secondary

Measure	Time frame
serum albumin;intestinal flora sequencing;blood urea nitrogen;urine protein creatinine ratio;uremia toxin;haemoglobin;blood creatinine;	—

Countries

China

Contacts

Public ContactYuan Xu

xyuan.0205@163.com13570576613

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026